Questcor Pharmaceuticals Inc (NASDAQ:QCOR) Director Stephen C. Farrell unloaded 10,000 shares of the company’s stock on the open market in a transaction dated Monday, April 7th. The stock was sold at an average price of $81.43, for a total value of $814,300.00. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) shares advanced 18.73% in last trading session and ended the day on $80.58. QCOR return on equity ratio is recorded as 94.20% and its return on assets is 50.60%.Questcor Pharmaceuticals Inc (NASDAQ:QCOR) yearly performance is 174.46%.
Repligen Corporation (RGEN), a technology leader in pre-packed columns for the cost-effective purification of biologic drugs, announced the commercial launch of its OPUS(R) 45 cm diameter columns (“OPUS 45”) with the largest capacity currently available on the market. OPUS columns, which now range from 1.2 cm to 45 cm in diameter, are delivered packed with chromatography media used to purify monoclonal antibodies and other biologic drugs. Repligen Corporation (NASDAQ:RGEN) shares advanced 6.33% in last trading session and ended the day on $14.10. RGEN return on equity ratio is recorded as 24. 50% and its return on assets is 21.70%. Repligen Corporation (NASDAQ:RGEN) yearly performance is 63.95%.
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) 25.8% HIGHER; announced that data from its lead, first-in-class program AG-221 will be presented at a Clinical Trials Symposium titled “Novel Immune and Targeted Therapies for Hematological Malignancies and Solid Tumors” at the American Association for Cancer Research (AACR) Annual Meeting 2014. These preliminary data demonstrate the clinical activity, tolerability and unique mechanism of action of AG-221 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-2 (IDH2) mutation. Agios Pharmaceuticals Inc (NASDAQ:AGIO) weekly performance is 15.84%. On last trading day company shares ended up $45.35. Agios Pharmaceuticals Inc (NASDAQ:AGIO) distance from 50-day simple moving average (SMA50) is 30.59%. Analysts mean target price for the company is $49.00.
New Haven Pharmaceuticals, a privately held specialty pharmaceuticals company, announced the appointment of Larry Dillaha, to the newly-created position of Executive Vice President Operations. Dr Dillaha joins the company from Insys Therapeutics Inc (NASDAQ: INSY) where he served as Chief Medical Officer since April 2010. Insys Therapeutics Inc (NASDAQ:INSY) weekly performance is -10.55%. On last trading day company shares ended up $37.06. Insys Therapeutics Inc (NASDAQ:INSY) distance from 50-day simple moving average (SMA50) is -12.44%. Analysts mean target price for the company is $62.00.